Improved Survival and Acceptable Complication Rates with Bidirectional Intraoperative Chemotherapy for Peritoneal Sarcomatosis

A retrospective cohort study analyzed 29 patients with peritoneal sarcomatosis who underwent cytoreductive surgery (CRS) with bidirectional intraoperative chemotherapy (BDIC) using intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC). The overall survival rates at 6, 12, 24, and 48 months after CRS/BDIC were 93.1%, 89.2%, 81.4%, and 73.3%, respectively. Disease recurrence rates were 15% at 6 months and 35% at 12, 24, and 48 months after CRS/BDIC. Complications were experienced by 31.0% of patients, but there were no deaths. BDIC shows potential as an effective treatment for peritoneal sarcomatosis.